未找到相关数据
Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study
被引：97
作者：
Qin, Shukui
Chen, Zhendong
Fang, Weijia
Ren, Zhenggang
Xu, Ruocai
Ryoo, Baek-Yeol
Meng, Zhiqiang
Bai, Yuxian
Chen, Xiaoming
Liu, Xiufeng
Xiao, Juxiang
Ho, Gwo Fuang
Mao, Yimin
Ye, Xing
Ying, Jieer
Li, Jianfeng
Zhong, Wen Yan
Zhou, Yu
Siegel, Abby B.
Hao, Chunyi
机构：
[1] Nanjing Chinese Med Univ, Jinling Hosp, Ctr Canc, Nanjing, Peoples R China
[2] Anhui Med Univ, Hosp 2, Hefei, Peoples R China
[3] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[5] Hunan Canc Hosp, Changsha, Peoples R China
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[7] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[8] Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Peoples R China
[9] Guangdong Prov Peoples Hosp, Dept Intervent Radiol, Guangzhou, Peoples R China
[10] Chinese PLA, Eastern Theater Gen Hosp, Nanjing, Peoples R China
[11] Xi An Jiao Tong Univ, Affiliated Hosp 1, Shaaxi, Peoples R China
[12] Univ Malaya, Dept Clin Oncol, Fac Med, Kuala Lumpur, Malaysia
[13] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai, Peoples R China
[14] Deyang Hosp, Deyang, Peoples R China
[15] Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp,Inst Canc & Basic Med IBMC, Hangzhou, Zhejiang, Peoples R China
[16] MSD China, Beijing, Peoples R China
[17] MSD China, Shanghai, Peoples R China
[18] Columbia Univ, New York, NY USA
[19] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.383
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
383
引用
收藏
页数：3
相关论文